Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP

Clinical Cancer Research

Volumn 18, Issue 24, 2012, Pages 6623-6633

  Yin, Shaoman ^a   Kaluz, Stefan ^a,b   Devi, Narra S ^a   Jabbar, Adnan A ^a   De Noronha, Rita G ^c,f   Mun, Jiyoung ^a   Zhang, Zhaobin ^a   Boreddy, Purushotham R ^e   Wang, Wei ^e   Wang, Zhibo ^a   Abbruscato, Thomas ^e   Chen, Zhengjia ^a   Olson, Jeffrey J ^a,b   Zhang, Ruiwen ^e   Goodman, Mark M ^a,b   Nicolaou, K C ^c,d   Van Meir, Erwin G ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIMETHOXY N [(2,2 DIMETHYL 2H CHROMEN 6 YL)METHYL] N PHENYLBENZENESULFONAMIDE; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; HISTONE ACETYLTRANSFERASE PCAF; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SULFONAMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; GENE TARGETING; GLIOBLASTOMA; GLUT1 GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SINGLE DRUG DOSE; TRANSCRIPTION TERMINATION; TREATMENT OUTCOME; TUMOR XENOGRAFT; VEGF GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CREB-BINDING PROTEIN; E1A-ASSOCIATED P300 PROTEIN; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INHIBITORY CONCENTRATION 50; LUCIFERASES, RENILLA; MICE; MICE, INBRED C57BL; MICE, NUDE; PROTEIN BINDING; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; SULFONAMIDES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866424379     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0861     Document Type: Article

References (50)

1. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncology 2005;7:134-53. (Pubitemid 40590514)
2. Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir EG. Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol 2002;9:24-36.
3. Tohma Y, Gratas C, Van Meir EG, Desbaillets I, Tenan M, Tachibana O, et al. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 1998;57:239-45. (Pubitemid 28125504)
4. Ruan K, Song G, Ouyang GL. Role of hypoxia in the hallmarks ofhuman cancer. J Cell Biochem 2009;107:1053-62.
5. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 2003;278:19575-8. (Pubitemid 36799137)
6. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402. (Pubitemid 351681994)
7. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005;2005:re12.
8. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004;23:4225-31. (Pubitemid 38758588)
9. Kasper LH, Fukuyama T, Biesen MA, Boussouar F, Tong CL, de Pauw A, et al. Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development. Mol Cell Biol 2006;26:789-809. (Pubitemid 43146476)
10. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A 2002;99:5367-72. (Pubitemid 34411554)
11. Ruas JL, Berchner-Pfannschmidt U, Malik S, Gradin K, Fandrey J, Roeder RG, et al. Complex regulation of the transactivation function of hypoxia-inducible factor-1 alpha by direct interaction with two distinct domains of the CREB-binding protein/p300. J Biol Chem 2010;285:2601-9.
12. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004;6:33-43. (Pubitemid 38903160)
13. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-15. (Pubitemid 28254373)
14. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW, et al. Evaluating Hypoxia-Inducible Factor-1a as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005;65:7249-58. (Pubitemid 41161256)
15. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625-34.
16. Lee K, Zhang HF, Qian DZ, Rey S, Liu JO, Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A 2009;106:17910-5.
17. Terzuoli E, Puppo M, Rapisarda A, Uranchimeg B, Cao LA, Burger AM, et al. Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1 alpha expression in an AhR-independent fashion. Cancer Res 2010;70:6837-48.
18. Schwartz DL, Bankson JA, Lemos R, Lai SY, Thittai AK, He Y, et al. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 2010;9:2057-67.
19. Mao SC, Liu Y, Morgan JB, Jekabsons MB, Zhou YD, Nagle DG. Lipophilic 2,5-disubstituted pyrroles from the marine sponge Mycale sp inhibit mitochondrial respiration and HIF-1 activation. J Nat Prod 2009;72:1927-36.
20. Belozerov VE, Van Meir EG. Inhibitors of hypoxia-inducible factor-1 signaling. Curr Opin Investig Drugs 2006;7:1067-76. (Pubitemid 44941751)
21. Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 2005;65:605-12.
22. Narita T, Yin S, Gelin CF, Moreno CS, Yepes M, Nicolaou KC, et al. Identification of a novel small molecule HIF-1α translation inhibitor. Clin Cancer Res 2009;15:6128-36.
23. Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z, et al. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res 2006;66:11991-7. (Pubitemid 46094213)
24. Kaluz S, Kaluzova M, Stanbridge EJ. Does inhibition of degradation of hypoxia-inducible factor (HIF) alpha always lead to activation of HIF? Lessons learnt from the effect of proteasomal inhibition on HIF activity. J Cell Biochem 2008;104:536-44. (Pubitemid 351671642)
25. Nicolaou KC, Pfefferkorn JA, Mitchell HJ, Roecker AJ, Barluenga S, Cao G-Q, et al. Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10,000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J Am Chem Soc 2000;122:9954-67.
26. Tan C, de Noronha RG, Devi NS, Jabbar AA, Kaluz S, Liu Y, et al. Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. Bioorg Med Chem Lett 2011;21:5528-32.
27. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:469-79. (Pubitemid 29316287)
28. Kaluz S, Kaluzova M, Stanbridge EJ. Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Res 2003;63:917-22. (Pubitemid 36278419)
29. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, et al. Identification of p53 as sequence-specific DNA-binding protein. Science 1991;252:1708-11. (Pubitemid 21917093)
30. Kaur B, Brat DJ, Devi NS, Van Meir EG. Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 2005;24:3632-42. (Pubitemid 40756232)
31. Kaur B, Cork SM, Sandberg EM, Devi NS, Zhang Z, Klenotic PA, et al. Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res 2009;69:1212-20.
32. Van Meir EG. Identification of nude mice in tumorigenicity assays. Int J Cancer 1997;71:310.
33. r-xenocat. [cited May 28 2012] Available from: http://code.google.com/p/ r-xenocat/.
34. Mooring SR, Jin H, Devi NS, Jabbar AA, Kaluz S, Liu Y, et al. Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. J Med Chem 2011;54:8471-89.
35. Mun J, Jabbar AA, Devi NS, Liu Y, Van Meir EG, Goodman MM. Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl) methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent. Bioorg Med Chem 2012;20:4590-7.
36. Mun J, Jabbar AA, Devi NS, Yin S, Wang Y, Tan C, et al. Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl) methyl]heteroarylsulfonamides, novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitors and anti-cancer agents. J Med Chem 2012;55:6738-50.
37. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 2001;8:1801-7. (Pubitemid 34100581)
38. Wang W, Ao L, Rayburn ER, Xu H, Zhang X, Xu Z, et al. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo antipancreatic cancer activities and preclinical pharmacology. PLOS One. 7(9): e44883. doi:10.1371/journal.pone.0044883.
39. Bowers VD, Locker S, Ames S, Jennings W, Corry RJ. The hemodynamic effects of Cremophor-EL. Transplantation 1991;51:847-50.
40. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8. (Pubitemid 32778603)
41. Shi Q, Yin S, Kaluz S, Ni N, Devi NS, Mun J, et al. Binding model for the interaction of anticancer arylsulfonamides with the p300 transcription cofactor. ACS Med Chem Lett 2012;3:620-5.
42. Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A, et al. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004;10:8603-12. (Pubitemid 40053428)
43. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003;22:2065-72. (Pubitemid 36539557)
44. Post DE, Sandberg EM, Kyle MM, Devi NS, Brat DJ, Xu Z, et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res 2007;67:6872-81. (Pubitemid 47105534)
45. Kim H, Peng G, Hicks JM, Weiss HL, Van Meir EG, Brenner MK, et al. Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther 2008;16:599-606. (Pubitemid 351315001)
46. Yang L, Cao Z, Li F, Post DE, Van Meir EG, Zhong H, et al. Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther 2004;11:1215-23. (Pubitemid 39136785)
47. Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005;16:901-9. (Pubitemid 41416080)
48. Semenza GL. HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des 2009;15:3839-43.
49. Kong DH, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 2005;65:9047-55. (Pubitemid 41377397)
50. Cook KM, Hilton ST, Mecinovic J, Motherwell WB, Figg WD, Schofield CJ. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1α (HIF-1α) and p300 by a zinc ejection mechanism. J Biol Chem 2009;284:26831-8.